StockLearn from Clustermicro · Stock Breakout ScannerStockLearn
← US stocks and world indices

Viatris (VTRS)

US-listed stock · Healthcare · Pharmaceuticals · close 18 Nov 2026
Close
$20.28
Day change
-0.8%
1 month
+8.7%
6 months
+22.9%
1 year
+89.4%
3 years
+114.6%
5 years
+51.5%
From 52-week high
-3.7%
Weinstein stage
Stage 2
advancing
Viatris closed at $20.28 on 18 Nov 2026. Over the past year it has gained 89.4%, and over five years +51% in all (+8.7% a year). It is 3.7% below its 52-week closing high of $21.06, set on 11 Nov 2026, and 99.0% above its 52-week closing low of $10.19. The price is above its 200-day average of $16.35 - an average that is itself still rising. On Stan Weinstein's stage analysis it is in Stage 2: advancing - above a rising 150-day average. Its deepest fall from a peak in the period shown was 80%. It made a loss over the last twelve months reported (to 31 Dec 2025), so it has no P/E. On revenue of $14.7B (+4.3% on a year earlier), the net margin was -23.9%.

Valuation and profitability

Market value
$23.3B
P/E (TTM)
loss
Price / book
1.7
Net margin
-23.9%
Return on equity
-25.7%
Revenue growth
+4.3%
Net income growth
—

From the company's SEC filings: the last twelve months to 31 Dec 2025, built from its 10-K and 10-Q reports. P/E and market value use the 18 Nov 2026 close, with the latest quarter's diluted share count; P/E is market value over net income, which stays right through a stock split. Growth compares with the twelve months a year earlier.

Price, RSI and MACD

Price · +23.2% over the period
1315171922May 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26
RSI (14) · 61.4
305070
MACD (12, 26, 9) · histogram +0.03
-0.3-00.30.60.9
Price · +89.4% over the period
912151922Nov 25Jan 26Mar 26May 26Jul 26Sep 26Nov 26
RSI (14) · 61.4
305070
MACD (12, 26, 9) · histogram +0.03
-0.5-0.10.30.61
Price · +60.7% over the period
710141822Nov 24Mar 25Jul 25Nov 25Mar 26Jul 26Nov 26
RSI (14) · 61.4
305070
MACD (12, 26, 9) · histogram +0.03
-0.8-0.30.10.61
Price · +120.0% over the period
610141822Nov 23Apr 24Sep 24Feb 25Jul 25Dec 25May 26Oct 26
RSI (14) · 61.4
305070
MACD (12, 26, 9) · histogram +0.03
-0.8-0.30.10.61
Price · +40.2% over the period
610141821Aug 22May 23Feb 24Nov 24Aug 25May 26
RSI (14) · 61.4
305070
MACD (12, 26, 9) · histogram +0.03
-1.5-0.8-0.20.41.1
Price: daily close adjusted for stock splits, dashed line the 150-day moving average. MACD: green line, orange dashed signal, bars the histogram. Longer periods are drawn from every second or third session.

50-day average $18.34 · 200-day average $16.35 · 52-week closing range $10.19 – $21.06

Other Healthcare stocks

NameClose1M1Y5YP/EStage
Merck$137.78-5.6%+42.9%+65.9%139.22
Johnson & Johnson$272.70+6.7%+36.3%+67.9%41.52
Eli Lilly$1,382.75+10.0%+34.2%+429.1%44.82
Gilead Sciences$168.98+8.2%+32.9%+149.3%loss2
Regeneron Pharmaceuticals$945.53+19.6%+30.4%+45.8%20.72
Amgen$443.89+2.6%+29.0%+117.6%25.82
Bristol Myers Squibb$59.56-0.3%+26.6%+0.9%13.22
McKesson$1,084.43+7.9%+26.0%+381.0%26.92
Vertex Pharmaceuticals$536.45+7.3%+23.2%+189.3%34.42
AbbVie$286.01+0.2%+22.3%+144.3%49.02
Thermo Fisher$692.74+0.4%+20.3%+8.6%36.32
UnitedHealth$349.91-12.8%+11.6%-22.2%19.93
Pfizer$28.06-5.1%+10.3%-45.4%40.02
CVS Health$81.35-11.9%+4.4%-14.7%9.53
Danaher Corporation$228.58-0.2%+1.4%-17.5%37.32
Medtronic$100.72+6.3%-0.1%-14.4%24.72
HCA Healthcare$476.35+3.8%-0.4%+95.8%15.31
Stryker Corporation$318.15+8.0%-11.5%+22.5%33.81
Abbott Laboratories$104.48-0.4%-19.6%-18.1%38.62
Intuitive Surgical$420.95-1.3%-23.0%+17.2%50.01

← All US stocks and world indices · NSE stocks

Daily closes to 18 Nov 2026, adjusted for stock splits (not dividends), from Google Finance and Yahoo Finance. US stock prices in US dollars; index levels in points. Figures may be delayed and are for information only.
For research & education only — not investment advice or a recommendation to buy or sell any security. StockLearn is an independent product of ClusterMicro Technologies, not affiliated with or endorsed by any exchange or index provider. ClusterMicro Technologies is not a SEBI-registered investment adviser. Consult a SEBI-registered adviser before investing.